Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients.

Autor: Schweiger V; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Bellamoli P; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Taus F; Department of Diagnostics and Public Health, Section of Statistics, University of Verona, 37124 Verona, Italy., Gottin L; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Martini A; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Nizzero M; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Bonora E; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Del Balzo G; Department of Diagnostics and Public Health, Section of Forensic Medicine, University of Verona, 37129 Verona, Italy., Donadello K; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Secchettin E; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy., Finco G; Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy., Santis D; Head and Neck Department, University of Verona, 37129 Verona, Italy., Polati E; Anesthesiology, Intensive Care and Pain Therapy Center, Department of Surgery, University of Verona, 37124 Verona, Italy.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2024 Feb 17; Vol. 13 (4). Date of Electronic Publication: 2024 Feb 17.
DOI: 10.3390/jcm13041130
Abstrakt: Background: Migraine is a neurological disorder characterized by attacks of head pain with prevalent unilateral localization, moderate to high intensity and specifically associated accompanying symptoms.
Methods: In this retrospective observational study, we analyzed data regarding 209 patients who had previously been diagnosed with migraine and who were prescribed, between 2019 and 2022, subcutaneous injections of anti-CGRP monoclonal antibodies (mAbs) fremanezumab or galcanezumab or anti-CGRP receptors mAb erenumab regardless of the concomitant assumption of any other acute-phase or prophylactic migraine medication.
Results: Regarding efficacy, in the 205 analyzed patients, the change from baseline in terms of MIDAS, HIT-6, MMDs and MAD scores was statistically significant for erenumab and galcanezumab, while for fremanezumab a statistical significance was not achieved likely due to the small sample size. In the treated population, 36 patients (17.5%) reported AEs (pain during injection, transient injection site erythema, nausea, constipation and fatigue). Only 5 patients (2.4%) discontinued the treatment for AEs while 15 patients (7.3%) left for lack of efficacy.
Conclusions: this retrospective study comes out in favor of both significant efficacy and safety of anti-CGRP and anti-CGRP receptors mAbs in migraine patients. Further methodologically stronger studies are necessary to validate our observation.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje